Evidence map›Paper›PMID 39614037›Full record

ArticleDrug delivery and translational research2025

Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges.

Ali Taheri, Ruba Almasri, Anthony Wignall, Hayley B Schultz, Aurelia S Elz, Amin Ariaee, Kristen E Bremmell, Paul Joyce, Clive A Prestidge

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ali Taheri *Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-9958-2383
Ruba Almasri *Centre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-6911-4562
Anthony WignallCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-6564-7927
Hayley B SchultzCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-8856-0317
Aurelia S ElzCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-6768-8223
Amin AriaeeCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-4649-219X
Kristen E BremmellCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-7633-0562
Paul JoyceCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0003-3619-7901
Clive A PrestidgeCentre for Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. clive.prestidge@unisa.edu.au.ORCID 0000-0001-5401-7535

Funding

Australian Prostate Cancer Australian Prostate Cancer
6 · The paper itself

Abstract

Abiraterone acetate, a prodrug of abiraterone, is an effective antiandrogen for treating metastatic prostate cancer. However, its poor aqueous solubility restricts oral bioavailability to under 10% in fasted conditions. Additionally, its pharmacokinetics are significantly influenced by food intake, leading to variable exposure that can impact treatment safety and efficacy. To overcome these challenges, we developed a series of lipid-based formulations aimed at reducing food effects and enhancing the fasted bioavailability of abiraterone acetate by incorporating the drug into colloidal delivery systems. Medium- and long-chain self-nanoemulsifying drug delivery systems (MC-SNEDDS and LC-SNEDDS) were formulated with abiraterone acetate loading at 80% of their respective preconcentrate equilibrium solubility. In-vitro gastrointestinal lipolysis experiments demonstrated that the SNEDDS formulations increased drug solubilisation by over 6-fold compared to pure abiraterone acetate and over 2-fold compared to the reference product after 60 min in the intestinal environment. In-vivo pharmacokinetic studies in rats revealed that both MC-SNEDDS and LC-SNEDDS formulations, along with their enteric-coated (EC) forms, exhibited enhanced bioavailability, with EC-LC-SNEDDS providing the highest performance, demonstrating a 7.32-fold increase in abiraterone exposure compared to the reference. Strong correlations were observed between in-vitro solubilisation and in-vivo AUC

Indexed as

Abiraterone AcetateFood-Drug InteractionsLipidsAnimalsBiological AvailabilityDrug Delivery SystemsEmulsionsHumansMaleRatsRats, Sprague-DawleySolubilityAbiraterone AcetateEmulsionsLipidsAbiraterone acetateEnteric coatingFood effectLipid-based formulationProstate cancerSolubility

Identifiers

PMID39614037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.